

Precision Health Begins with Prevention

Clinically validated diagnostics powered by data-driven prediction



Global Burden of DKD

With 40% of diabetic patients worldwide (nearly half-a-billion) developing kidney complications, it has never been more critical to shift from diagnosis to prevention.*1

537m diabetic patients world-wide*2


40% (215m)
of diabetes patients will develop kidney complications including ESRD

50%ESRD patients die within 5 years & 20% die within 1 year*3

Up to 40%



of high-risk patients in non-albuminuric / proteinuric DKD pt. are unidentified by current detection methods



• IVD103 predicts the early critical shifts for the 4 key trajectories of kidney function in DKD

Adapted from Nat Rev Nephrol. 2021 [17]740-750.

DNlite-IVD103 Human uPTM3-DKD ELISA TEST

a Better Predictor to Assist DKD Risk Management of Patients Who Will Progress

During 1-2 yrs

eGFR progressive decline (-5 mL/min/1.73 m² per year)

During 2-5 yrs

Incident DKD (eGFR below 60 mL/min/1.73 m² or decreased by more than 30%) **During 5-10 yrs**

Renal function deterioration

[need for renal replacement therapy: kidney transplantation or dialysis; or serum creatinine increment >50% within 3 months]


DNlite-IVD103 Human uPTM3-DKD ELISA Test

Diabetic Kidney Disease

We are conquering the world of kidney disease and kidney injury by translating validated and IP-protected novel biomarkers into clinically-validated solutions.







Progression of Nephropathy: Time after diagnosis (years) J Clin Invest 2006; 116(2): 288-296.

DNLite IVD103 predicts renal function loss years in advance through non-invasive ELISA-based testing. A true diagnostic gold standard for DKD in clinics and labs.

DNlite IVD103 Human uPTM3-DKD ELISA Test

- Single and Unique Biomarker
- Predict Progressive Decliner
- Predicting & Monitoring Renal Function Loss
- Precision DKD Management
- Non-invasive Urinary ELISA Test



About BPM

BIO PREVENTIVE MEDICINE is a leading company in renal biomarker area. As a clinical staged IVD and biotech company, BPM focuses on translating validated and IP-protected novel biomarkers into diagnostic solutions for unmet clinical needs. For more information, please refer to BPM official website or contact us.



